Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
Rain Therapeutics (NasdaqGS: RAIN) announced its participation in Piper Sandler’s 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York. CEO Avanish Vellanki will join a fireside chat on December 1 at 1:30 p.m. ET. The event will be accessible via webcast. Rain Therapeutics specializes in precision oncology and is developing milademetan, an oral inhibitor targeting the MDM2-p53 complex to reactivate p53. The company also has a preclinical program aimed at inducing synthetic lethality in cancer cells through RAD52 inhibition.
- None.
- None.
NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler’s 34th Annual Healthcare Conference, being held November 29 – December 1, 2022, in New York.
Avanish Vellanki, chief executive officer of Rain, will be participating in a fireside chat on Thursday, December 1 at 1:30 p.m. ET. A webcast of the fireside chat can be accessed here. The Company’s management team will participate in one-on-one investor meetings. To request a meeting, please contact your Piper Sandler representative.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
FAQ
What is the purpose of Rain Therapeutics' participation in the Piper Sandler conference?
When will Rain Therapeutics CEO Avanish Vellanki speak at the conference?
How can investors access the webcast of Rain Therapeutics' fireside chat?
What is milademetan and its role in Rain Therapeutics' pipeline?
What is the focus of Rain Therapeutics' preclinical program?
